Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA6 | P23280 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | TPMT | P51580 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 4/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27185476 | 0.87 | KDM4E (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31510024 | 0.87 | KDM4E (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9907496 | 0.83 | CCR1 (0.47) | PKMTPMTKDM4CKDM5AKDM5B | |
| SCHEMBL16533111 | 0.82 | CA12 (0.47) | CA12CA1CA2CA4CA6 | |
| SCHEMBL9909167 | 0.80 | CCNT1 (0.42) | KDM4CKDM5AKDM5BKDM4EKDM6B | |
| SCHEMBL9104437 | 0.80 | KDM4E (0.41) | CA12CA1CA2CA4CA6 | |
| SCHEMBL9909250 | 0.78 | LMNA (0.41) | CA12CA1CA2CA4CA6 | |
| SCHEMBL9909218 | 0.76 | PRKAB2 (0.39) | KDM4CPTGS2KDM5AKDM5BHTT | |
| Hydrochloric Acid SCHEMBL18109880 | 0.76 | CA12 (0.53) | CA12CA1CA2CA4CA6 | |
| SCHEMBL27185251 | 0.75 | EGFR (0.43) | SRCTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4562017-A1 | NOVEL ACC INHIBITORS | Pfizer Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-120019059-A | Novel ACC inhibitors | 辉瑞公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20240109915-A1 | NOVEL ACC INHIBITORS | PFIZER INC. (US) | 2024-04-04 | — | — | US | disclosed |
| WO-2024023727-A1 | NOVEL ACC INHIBITORS | PFIZER INC. (US) | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109915-A1 | NOVEL ACC INHIBITORS | CBR3, NAT1, ACACB | CA12 1526/4885CA1 765/4885CA2 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.